Literature DB >> 9192444

Estimating medical costs from incomplete follow-up data.

D Y Lin1, E J Feuer, R Etzioni, Y Wax.   

Abstract

Estimation of the average total cost for treating patients with a particular disease is often complicated by the fact that the survival times are censored on some study subjects and their subsequent costs are unknown. The naive sample average of the observed costs from all study subjects or from the uncensored cases only can be severely biased, and the standard survival analysis techniques are not applicable. To minimize the bias induced by censoring, we partition the entire time period of interest into a number of small intervals and estimate the average total cost either by the sum of the Kaplan-Meier estimator for the probability of dying in each interval multiplied by the sample mean of the total costs from the observed deaths in that interval or by the sum of the Kaplan-Meier estimator for the probability of being alive at the start of each interval multiplied by an appropriate estimator for the average cost over the interval conditional on surviving to the start of the interval. The resultant estimators are consistent if censoring occurs solely at the boundaries of the intervals. In addition, the estimators are asymptotically normal with easily estimated variances. Extensive numerical studies show that the asymptotic approximations are adequate for practical use and the biases of the proposed estimators are small even when censoring may occur in the interiors of the intervals. An ovarian cancer study is provided.

Entities:  

Mesh:

Year:  1997        PMID: 9192444

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  104 in total

1.  Expressing estimators of expected quality adjusted survival as functions of Nelson-Aalen estimators.

Authors:  Y Huang; T A Louis
Journal:  Lifetime Data Anal       Date:  1999-09       Impact factor: 1.588

2.  Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting.

Authors:  Marcus A Neubauer; J Russell Hoverman; Michael Kolodziej; Lonny Reisman; Stephen K Gruschkus; Susan Hoang; Albert A Alva; Marilyn McArthur; Michael Forsyth; Todd Rothermel; Roy A Beveridge
Journal:  J Oncol Pract       Date:  2009-12-30       Impact factor: 3.840

3.  Providing systematic guidance in pharmacoeconomic guidelines for analysing costs.

Authors:  Philip Jacobs; Arto Ohinmaa; Bruce Brady
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trial.

Authors:  Andre Konski; Mythreyi Bhargavan; Jean Owen; Rebecca Paulus; Jay Cooper; Karen K Fu; Kian Ang; Deborah Watkins-Bruner
Journal:  J Med Econ       Date:  2008       Impact factor: 2.448

5.  Current Methods for Recurrent Events Data with Dependent Termination: A Bayesian Perspective.

Authors:  Debajyoti Sinha; Tapabrata Maiti; Joseph G Ibrahim; Bichun Ouyang
Journal:  J Am Stat Assoc       Date:  2008-06-01       Impact factor: 5.033

6.  Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

Authors:  V F Fragoulakis; A G Pallis; D K Kaitelidou; N M Maniadakis; V G Georgoulias
Journal:  Lung Cancer (Auckl)       Date:  2012-07-16

7.  EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT.

Authors:  Elizabeth A Handorf; Justin E Bekelman; Daniel F Heitjan; Nandita Mitra
Journal:  Ann Appl Stat       Date:  2013       Impact factor: 2.083

8.  Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.

Authors:  Silas C Martin; Dennis D Gagnon; Lucy Zhang; Carsten Bokemeyer; Marinus Van Marwijk Kooy; Ben van Hout
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Methods to analyse cost data of patients who withdraw in a clinical trial setting.

Authors:  Jan B Oostenbrink; Maiwenn J Al; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.

Authors:  J Jayasekera; E Onukwugha; K Bikov; C D Mullins; B Seal; A Hussain
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.